MedTrace Logo

Adjunctive Celecoxib in Childhood-onset OCD Study

NCT04673578 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2022-12-16

No results posted yet for this study

Summary

This is a randomized, controlled, single-centre phase II superiority trial to determine the efficacy of 12 weeks of celecoxib (50 mg or 100 mg orally twice daily, dosed based on weight) compared to placebo as an adjunct to treatment-as-usual in children and youth with moderate-to-severe obsessive-compulsive disorder.

Conditions

  • Obsessive-Compulsive Disorder
  • Pediatric Psychiatric Disorder

Interventions

DRUG

Celecoxib

Selective COX-2 inhibitor; nonsteroidal anti-inflammatory drug (NSAID)

OTHER

Placebo

Microcrystalline cellulose

Sponsors & Collaborators

  • BC Children's Hospital Research Institute

    collaborator OTHER

  • Obsessive Compulsive Foundation

    collaborator OTHER

  • University of British Columbia

    lead OTHER

Principal Investigators

  • S. Evelyn Stewart, MD · University of British Columbia; BC Children's Hospital Research Institute

  • Clara Westwell-Roper, MD, PhD · University of British Columbia; BC Children's Hospital Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
7 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2023-06-30
Completion
2023-06-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04673578 on ClinicalTrials.gov